Abbonarsi

Covid-19 psychological distress: Analysis of antipsychotic drugs’ use in an Italian population sample - 04/05/24

Détresse psychologique Covid-19 : analyse de l’utilisation d’antipsychotiques dans un échantillon de la population italienne

Doi : 10.1016/j.pharma.2024.04.007 
Francesco Ferrara a, 1, , Maurizio Capuozzo b, 1, Ugo Trama c, Eduardo Nava a, Roberto Langella d, Filomena Valentino e, Andrea Zovi f
a Pharmaceutical department, Asl Napoli 3 Sud, 22, Dell’amicizia street, 80035 Nola, Naples, Italy 
b Pharmaceutical department, Asl Napoli 3 Sud, 3, Marittima street, 80056 Ercolano, Naples, Italy 
c General Direction for Health Protection and Coordination of the Campania Regional Health System, Naples, Italy 
d Italian Society of Hospital Pharmacy (SIFO), SIFO Secretariat of the Lombardy Region, 81, Carlo-Farini street, 20159 Milan, Italy 
e University of Milan, 7, Festa-del-Perdono street, 20122 Milano, Italy 
f Ministry of Health, 5, viale Giorgio-Ribotta, 00144 Rome, Italy 

Corresponding author.

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
Articolo gratuito.

Si connetta per beneficiarne

In corso di stampa. Prove corrette dall'autore. Disponibile online dal Saturday 04 May 2024

Highlights

Psychiatric disorders were important during and after the Covid-19 pandemic.
Antipsychotic consumption was lower than expected due to a lack of access to hospital facilities.
Long Covid is still present and central nervous system disorders are among the major problems inherited from the long pandemic period.

Il testo completo di questo articolo è disponibile in PDF.

Summary

Background

The current pandemic, in addition to putting a strain on healthcare systems and global economies, has exacerbated psychiatric problems and undermined the mental health of many individuals. In an Italian cohort, this phenomenon has been assessed through a retrospective study aimed at evaluating the consumption and costs of antipsychotic drugs between 2020 and 2022.

Methods

All dispensations made in local pharmacies accessible to the public have been extracted from a database called ‘Sistema Tessera Sanitaria’, which covers a population of approximately one million people residents in the ASL Napoli 3 Sud. Consumption data expressed in defined daily dose (DDD) and expenditure data expressed in Euro have been extrapolated.

Results

The results in the years 2020–2021 were relatively consistent, with consumption and expenditure decreasing slightly from 2020 to 2021. In 2022, the results showed a decrease in consumption and expenditure (2,706,951.07 DDD and €1,700,897.47) representing the reduced accessibility of patients to the healthcare facilities due to the pandemic. However, it should be noted that the antipsychotic drug aripiprazole showed an upward trend, registering an increase in consumption.

Conclusion

Despite expectations of increased consumption of antipsychotic medications, real-world evidence indicated a different phenomenon, with the pandemic seemingly not affecting the consumption of these drugs. The difficulty in accessing care and medical appointments has probably influenced this data, masking the therapeutic needs of citizens. It will be necessary to assess in the coming years, as normal clinical activity resumes, whether there will be a growing consumption of these medications, which represent one of the main expenditure categories for the National Healthcare System.

Il testo completo di questo articolo è disponibile in PDF.

Résumé

Contexte

La pandémie actuelle, en plus de mettre à rude épreuve les systèmes de santé et les économies mondiales, a exacerbé les problèmes psychiatriques et miné la santé mentale de nombreux individus. Il est bien connu que les événements épidémiques, en particulier les périodes de confinement, augmentent le risque de développer des troubles anxieux, des dépressions et des comportements agressifs.

Méthodes

Dans une cohorte italienne, ce phénomène a été évalué par le biais d’une étude rétrospective visant à évaluer la consommation et les coûts des médicaments antipsychotiques pendant et après la pandémie de Covid-19 dans les années 2020–2022. Toutes les ordonnances délivrées dans les pharmacies locales accessibles au public ont été extraites d’une base de données appelée Health Card System, couvrant une population d’environ un million de personnes.

Résultats

Les résultats pour les années 2020 à 2021 sont relativement cohérents, la consommation et les dépenses ayant légèrement diminué entre 2020 et 2021. Cependant, le médicament antipsychotique aripiprazole a montré une tendance à la hausse, enregistrant une augmentation de la consommation.

Conclusion

Malgré les attentes d’une augmentation de la consommation de médicaments antipsychotiques, les données réelles indiquent un phénomène différent, la pandémie ne semblant pas affecter la consommation de ces médicaments. La difficulté d’accès aux soins et aux rendez-vous médicaux a probablement influencé ces données, masquant les besoins thérapeutiques des citoyens. Il sera nécessaire d’évaluer dans les années à venir, lorsque l’activité clinique normale reprendra, si la consommation de ces médicaments, qui représentent l’une des principales catégories de dépenses pour le système national de soins de santé, augmentera.

Il testo completo di questo articolo è disponibile in PDF.

Keywords : Antipsychotic, Retrospective study, Covid-19, Pandemic, Neurological problems, Pharmaco-utilization

Mots clés : Antipsychotique, Étude rétrospective, Covid-19, Pandémie, Problèmes neurologiques, Pharmaco-utilisation


Mappa


© 2024  Académie Nationale de Pharmacie. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2024 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.